UNSPSC 51141504: Lamotrigine

This classification denotes an anticonvulsant agent with the molecular formula C9H7Cl2N5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier U3H27498KS, chemically known as 1,2,4-triazine-3,5-diamine, 6-(2,3-dichlorophenyl)- but generally known as lamotrigine, which bears US NIH Compound Identifier 3878. European Medicines Agency schedules Lamotrigine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08393MIG.

UNSPSC 51141504 Lamotrigine is a Commodity code for a specific anticonvulsant pharmaceutical, yet recent state and local opportunities posted under this code do not actually procure lamotrigine itself. Instead, the tagged solicitations seek naloxone, safe drug deactivation systems, generic multi-source pharmaceuticals and over-the-counter products, and direct-to-manufacturer prescription program infrastructure. The mismatch between the code's nominal scope and the work being solicited suggests this code sees limited relevant recent activity for firms focused on the specific pharmaceutical named. State and local governments use the broader pharmaceutical and health-services codes to procure emergency medications, community health supplies, and pharmacy benefit program administration across multiple issuing bodies including county health departments, state health and human services commissions, and multistate cooperative purchasing alliances.

Recent opportunities show activity in Florida and Minnesota, with a Request for Information from the Texas Health and Human Services Commission. Seminole County, Florida released IFB60459723LAS on June 30, 2026 (due July 26, 2023) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued an RFP on January 20, 2026 (due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities, with awarded vendors effective July 1, 2026. The Texas Health and Human Services Commission posted RFI No. HHS0017013 on April 3, 2026 to solicit vendor capabilities regarding a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, signaling state-level interest in restructured pharmacy benefit procurement outside traditional PBM and GPO channels.